Community-Acquired Bacterial Pneumonia Market Poised for Expansion During the Forecast Period (2026-2036) Amid Rising Antimicrobial Resistance and Therapeutic Advances | DelveInsight
The community-acquired bacterial pneumonia market is poised for continued growth, driven by the substantial global disease burden, increasing hospitalization rates, an aging population, rising prevalence of comorbidities, and the growing challenge of antimicrobial resistance. Additionally, the launch of emerging therapies such as CAL02 (Eagle Pharmaceutical/Combioxin), AON-D21 (APTARION Biotech), Trimodulin (BT588; Biotest AG), and others will further propel market growth.
LAS VEGAS, Sept. 7, 2026 /PRNewswire/ -- Recently published Community-Acquired Bacterial Pneumonia Market Insights report includes a comprehensive understanding of current treatment practices, community-acquired bacterial pneumonia emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Community-Acquired Bacterial Pneumonia Market Summary
Discover CABP clinical trial 2026 update press release @ https://www.delveinsight.com/report-store/community-acquired-bacterial-pneumonia-cabp-market
Key Factors Driving the Growth of the Community-Acquired Bacterial Pneumonia Market
Aparna Thakur, Project Manager of Forecasting & Analytics at DelveInsight, said that emerging candidates such as CAL02 and AON-D21 are being developed to complement conventional antibiotic treatment by targeting bacterial toxins, virulence factors, and host inflammatory responses. These novel approaches aim to improve clinical outcomes in severe CABP and address challenges associated with antimicrobial resistance and treatment failure.
Community-Acquired Bacterial Pneumonia Market Analysis
Community-Acquired Bacterial Pneumonia Competitive Landscape
Some of the CABP drugs under development include CAL02 (Eagle Pharmaceutical/Combioxin), AON-D21 (APTARION Biotech), Trimodulin (BT588; Biotest AG), and others.
Eagle Pharmaceutical/Combioxin's CAL02 is a Phase II-stage therapeutic candidate being developed to address severe infections, particularly community-acquired pneumonia (CAP) among critically ill ICU patients. The treatment consists of liposomes formulated with cholesterol and sphingomyelin, with sphingomyelin incorporated for its distinctive anti-infective properties. This formulation highlights the therapeutic potential of antimicrobial lipids in combating bacterial infections.
CAL02 works by neutralizing bacterial virulence effectors, which play a significant role in the development of organ dysfunction and life-threatening complications associated with severe infections. By targeting these virulence mechanisms rather than solely focusing on bacterial eradication, CAL02 aims to limit disease progression and potentially improve clinical outcomes.
The candidate has received Fast Track and Qualified Infectious Disease Product (QIDP) designations from the U.S. FDA. These regulatory designations can provide an additional five years of market exclusivity, potentially extending the total exclusivity period to eight or ten years.
APTARION Biotech's AON-D21 is another therapeutic candidate currently undergoing Phase II clinical development. It is a PEGylated, L-configured aptamer, a synthetic molecule engineered to selectively bind to specific biological targets. AON-D21 is designed to modulate the complement pathway by selectively binding to and neutralizing C5a, a key component of the immune system.
C5a serves as an important mediator of immune activity and plays a central role in coordinating inflammatory responses. Its broad involvement in immune regulation creates opportunities for C5a-targeted therapies across multiple disease areas, particularly conditions in which excessive or dysregulated immune responses contribute to disease progression.
The anticipated launch of these emerging therapies are poised to transform the CABP market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the CABP market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about the latest treatments for CABP 2026 @ Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials
Community-Acquired Bacterial Pneumonia Epidemiology Segmentation
The CABP epidemiology section provides insights into the historical and current CABP patient pool and forecasted trends for the leading markets. In the US, mild cases of CABP constituted the highest proportion, approximately 50% of total incident cases, followed by moderate cases at around 35%.
The CABP treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:
Community-Acquired Bacterial Pneumonia Market Report Metrics
Details
Study Period
2022–2036
Coverage
7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Community-Acquired Bacterial Pneumonia Epidemiology Segmentation
Total Incident Cases of CABP, Gender-specific Cases of CABP, Severity-specific Cases of CABP, Pathogens-specific Cases of CABP, Age-specific Cases of CABP, and Total Treated Cases of CABP
Key Community-Acquired Bacterial Pneumonia Companies
Eagle Pharmaceutical, Combioxin, APTARION Biotech, Biotest AG, Nabriva Therapeutics, Paratek Pharmaceutical, and others
Key Community-Acquired Bacterial Pneumonia Therapies
CAL02, AON-D21, Trimodulin (BT588), XENLETA, NUZYRA, and others
Scope of the Community-Acquired Bacterial Pneumonia Market Report
Download the report to understand the CABP treatment market @ Community-Acquired Bacterial Pneumonia Drugs
Table of Contents
1
Community-Acquired Bacterial Pneumonia Market Key Insights
2
Community-Acquired Bacterial Pneumonia Market Report Introduction
3
Executive Summary
4
Key Events
5
Epidemiology and Market Methodology
6
Community-Acquired Bacterial Pneumonia (CABP) Market Overview at a Glance
6.1
Clinical Landscape Analysis (By Phase, Molecule Type, and RoA)
6.2
Market Share (%) Distribution of CABP by Therapies in the 7MM, in 2025
6.3
Market Share (%) Distribution of CABP by Therapies in the 7MM, in 2036
7
Disease Background and Overview
7.1
Introduction
7.2
Etiology
7.3
Pathophysiology
7.4
Signs and Symptoms of CABP
7.5
Clinical Characteristics
7.6
Immunology & Risk Factors
7.7
Diagnosis
7.8
Prognosis
7.9
Diagnostic Biomarkers for CABP
8
Treatment and Management
8.1
Antibiotic therapy
8.2
Diuretics
8.3
Corticosteroids
8.4
Later management
8.5
Diagnostic and Treatment Guidelines
9
Epidemiology and Patient Population
9.1
Key Findings
9.2
Assumptions and Rationale
9.3
Total Incident Cases of Community-Acquired Bacterial Pneumonia (CABP) in the 7MM
9.4
The United States
9.5.1
Incident Cases of Community-Acquired Bacterial Pneumonia (CABP)
9.5.2
Gender-specific Cases of Community-Acquired Bacterial Pneumonia (CABP)
9.5.3
Severity-specific Cases of Community-Acquired Bacterial Pneumonia (CABP)
9.5.4
Pathogen-specific Cases of Community-Acquired Bacterial Pneumonia (CABP)
9.5.5
Age-specific Cases of Community-Acquired Bacterial Pneumonia (CABP)
9.5.6
Total treated Cases of Community-Acquired Bacterial Pneumonia (CABP)
9.6
EU4 and the UK
9.7
Japan
10
Patient Journey
11
Marketed CABP Therapies
11.1
Marketed Competitive Landscape
11.2
Lefamulin (XENLETA): Nabriva Therapeutics
11.2.1
Drug Description
11.2.2
Regulatory Milestones
11.2.3
Other Developmental Activities
11.2.4
Summary of Pivotal Trials
11.2.5
Clinical Development
11.2.5.1
Clinical Trial Information
11.2.6
Safety and Efficacy
11.2.7
Analyst's Views
11.3
Omadacycline (NUZYRA): Paratek Pharmaceuticals
List will be continued in the report…
12
Emerging CABP Drugs
12.1
Emerging Competitive Landscape
12.2
CAL02: Eagle Pharmaceutical/Combioxin SA
12.2.1
Drug Description
12.2.2
Other Developmental Activities
12.2.3
Clinical Development
12.2.3.1
Clinical Trials Information
12.2.4
Safety and Efficacy
12.2.5
Analyst's Views
12.3
AON-D21 (anti-C5a): APTARION Biotech AG
List will be continued in the report…
13
Other Therapies: Generics
13.1
Amoxicillin
13.2
Azithromycin
13.3
Clarithromycin
13.4
Doxycycline
13.5
Moxifloxacin
13.6
Vaccine
14
Community-Acquired Bacterial Pneumonia Market: 7MM Analysis
14.1
Key Findings
14.2
Community-Acquired Bacterial Pneumonia Market Outlook
14.3
Conjoint analysis
14.4
Key Community-Acquired Bacterial Pneumonia Market Forecast Assumptions
14.5
Total Market Size of Community-Acquired Bacterial Pneumonia (CABP) in the 7 MM
14.6
Market Size of Community-Acquired Bacterial Pneumonia (CABP) by Therapies In 7MM
14.7
The United States CABP Market Size
14.7.1
Total Market Size of Community-Acquired Bacterial Pneumonia (CABP) in the United States
14.7.2
Market Size of Community-Acquired Bacterial Pneumonia (CABP) by Therapies in the United States
14.8
EU4 and the UK CABP Market
14.9
Japan CABP Market Size
15
KOL Views
16
Unmet Needs
17
SWOT Analysis
18
CABP Market Access and Reimbursement
19
Bibliography
20
Community-Acquired Bacterial Pneumonia Market Report Methodology
Related Reports
Community-Acquired Bacterial Pneumonia Clinical Trial Analysis
Community-Acquired Bacterial Pneumonia Pipeline – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key CABP companies, including Mesoblast, Taiwan Liposome Company, Biosplice, Centrexion Therapeutics, Latigo Biotherapeutics, Pacira BioSciences, Contineum Therapeutics, Tris Pharma, Flexion, Taisho Pharmaceutical, Bioventus, and others.
Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia Market
Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key HABP/VABP companies, including Basilea, Merck, Shionogi, Pfizer, Aridis Pharmaceuticals, Polyphor, Aerucin, Motif Bio, and others.
Pneumonia Market
Pneumonia Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key pneumonia companies including Aridis Pharmaceuticals, Aptarion Biotech, Biotest AG, Vaxcyte, Inc., CanSinoBIO, Inventprise, BioVersys, and others.
Bacterial Pneumonia Market
Bacterial Pneumonia Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key bacterial pneumonia companies including Pfizer, Forecast Laboratories, Melinta Therapeutics Inc., Merck Sharp & Dohme LLC, Melinta Therapeutics Inc., Evopoint Biosciences Inc., Paratek Pharmaceuticals Inc., Wockhardt, Clarametyx Biosciences Inc., AstraZeneca, Cumberland Pharmaceuticals, Eagle Pharmaceuticals Inc., Bayer, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
[email protected]
+14699457679
www.delveinsight.com
SOURCE DelveInsight Business Research, LLP